| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 41 | 2024 | 586 | 8.270 |
Why?
|
| Cerebellar Neoplasms | 32 | 2024 | 486 | 7.810 |
Why?
|
| Proton Therapy | 37 | 2024 | 1638 | 5.540 |
Why?
|
| Craniospinal Irradiation | 17 | 2024 | 133 | 4.830 |
Why?
|
| Wilms Tumor | 26 | 2024 | 302 | 3.720 |
Why?
|
| Rhabdomyosarcoma | 13 | 2019 | 343 | 3.050 |
Why?
|
| Brain Neoplasms | 53 | 2023 | 4993 | 2.940 |
Why?
|
| Child, Preschool | 123 | 2024 | 16999 | 2.680 |
Why?
|
| Child | 166 | 2024 | 30492 | 2.500 |
Why?
|
| Radiotherapy Dosage | 55 | 2024 | 4003 | 2.370 |
Why?
|
| Neuroblastoma | 11 | 2022 | 703 | 2.190 |
Why?
|
| Ependymoma | 14 | 2024 | 269 | 2.050 |
Why?
|
| Cochlea | 6 | 2024 | 118 | 1.960 |
Why?
|
| Neoplasms, Radiation-Induced | 9 | 2021 | 404 | 1.950 |
Why?
|
| Radiation Oncology | 12 | 2024 | 558 | 1.900 |
Why?
|
| Sarcoma, Ewing | 10 | 2024 | 426 | 1.880 |
Why?
|
| Cranial Irradiation | 14 | 2018 | 322 | 1.820 |
Why?
|
| Adolescent | 116 | 2024 | 32663 | 1.750 |
Why?
|
| Radiotherapy | 19 | 2020 | 1860 | 1.750 |
Why?
|
| Radiation Injuries | 21 | 2024 | 1472 | 1.700 |
Why?
|
| Hearing Loss | 3 | 2024 | 173 | 1.670 |
Why?
|
| Scoliosis | 4 | 2022 | 148 | 1.650 |
Why?
|
| Photons | 8 | 2024 | 537 | 1.630 |
Why?
|
| Kidney Neoplasms | 26 | 2024 | 3153 | 1.560 |
Why?
|
| Infant | 72 | 2024 | 13931 | 1.520 |
Why?
|
| Bone Neoplasms | 15 | 2024 | 2668 | 1.510 |
Why?
|
| Combined Modality Therapy | 49 | 2023 | 9044 | 1.480 |
Why?
|
| Radiotherapy, Conformal | 16 | 2023 | 898 | 1.460 |
Why?
|
| Radiotherapy, Intensity-Modulated | 16 | 2023 | 2168 | 1.420 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2024 | 10365 | 1.390 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 4 | 2021 | 64 | 1.370 |
Why?
|
| Glioma | 16 | 2023 | 1988 | 1.350 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2021 | 76 | 1.330 |
Why?
|
| Head and Neck Neoplasms | 24 | 2021 | 4137 | 1.240 |
Why?
|
| Hypothyroidism | 4 | 2022 | 211 | 1.190 |
Why?
|
| Meningeal Neoplasms | 7 | 2012 | 473 | 1.150 |
Why?
|
| Humans | 250 | 2024 | 271884 | 1.140 |
Why?
|
| Male | 149 | 2024 | 128957 | 1.100 |
Why?
|
| Protons | 12 | 2023 | 483 | 1.010 |
Why?
|
| Female | 145 | 2024 | 149143 | 0.970 |
Why?
|
| Cisplatin | 5 | 2024 | 2497 | 0.920 |
Why?
|
| Cancer Survivors | 9 | 2023 | 744 | 0.920 |
Why?
|
| Neoplasms, Second Primary | 11 | 2021 | 1388 | 0.860 |
Why?
|
| Radiotherapy, Adjuvant | 16 | 2023 | 2270 | 0.850 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 17 | 2023 | 2452 | 0.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2024 | 16610 | 0.820 |
Why?
|
| Follow-Up Studies | 33 | 2024 | 15267 | 0.820 |
Why?
|
| Survival Rate | 35 | 2024 | 12533 | 0.810 |
Why?
|
| Craniopharyngioma | 3 | 2023 | 56 | 0.800 |
Why?
|
| Treatment Failure | 14 | 2021 | 1432 | 0.790 |
Why?
|
| Lymphopenia | 1 | 2024 | 211 | 0.790 |
Why?
|
| Pituitary Neoplasms | 4 | 2023 | 218 | 0.770 |
Why?
|
| Retrospective Studies | 59 | 2024 | 39780 | 0.740 |
Why?
|
| Germinoma | 3 | 2011 | 84 | 0.730 |
Why?
|
| Young Adult | 38 | 2024 | 22108 | 0.720 |
Why?
|
| Brain Stem | 6 | 2024 | 185 | 0.720 |
Why?
|
| Brain Stem Neoplasms | 5 | 2020 | 102 | 0.720 |
Why?
|
| Radiation Oncologists | 1 | 2020 | 31 | 0.720 |
Why?
|
| Astrocytoma | 7 | 2021 | 335 | 0.720 |
Why?
|
| Hodgkin Disease | 6 | 2020 | 1488 | 0.700 |
Why?
|
| Radiosurgery | 10 | 2014 | 1368 | 0.690 |
Why?
|
| Prognosis | 47 | 2024 | 22537 | 0.690 |
Why?
|
| Positron-Emission Tomography | 7 | 2011 | 2198 | 0.660 |
Why?
|
| Vincristine | 10 | 2024 | 1572 | 0.660 |
Why?
|
| Sarcoma | 8 | 2022 | 1842 | 0.660 |
Why?
|
| Lymphatic Metastasis | 11 | 2020 | 4968 | 0.660 |
Why?
|
| Disease-Free Survival | 22 | 2024 | 10259 | 0.660 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2022 | 917 | 0.650 |
Why?
|
| Orbital Neoplasms | 4 | 2020 | 237 | 0.640 |
Why?
|
| Neoplasms | 19 | 2024 | 15915 | 0.640 |
Why?
|
| Radiopharmaceuticals | 8 | 2014 | 1338 | 0.640 |
Why?
|
| Adult | 75 | 2024 | 81857 | 0.630 |
Why?
|
| Radiotherapy, High-Energy | 5 | 2009 | 303 | 0.630 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 234 | 0.630 |
Why?
|
| Teratoma | 3 | 2023 | 253 | 0.600 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2011 | 1259 | 0.590 |
Why?
|
| Neoplasm Staging | 27 | 2024 | 13993 | 0.580 |
Why?
|
| Neoplasm, Residual | 4 | 2019 | 1741 | 0.570 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 671 | 0.570 |
Why?
|
| Neuroectodermal Tumors | 3 | 2004 | 33 | 0.560 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2016 | 337 | 0.550 |
Why?
|
| Treatment Outcome | 42 | 2024 | 33863 | 0.550 |
Why?
|
| Cognition | 8 | 2022 | 982 | 0.550 |
Why?
|
| Organ Sparing Treatments | 2 | 2018 | 280 | 0.550 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 313 | 0.520 |
Why?
|
| Survival Analysis | 23 | 2018 | 9325 | 0.520 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2021 | 6270 | 0.510 |
Why?
|
| Age Factors | 15 | 2024 | 5520 | 0.510 |
Why?
|
| Re-Irradiation | 3 | 2024 | 166 | 0.490 |
Why?
|
| Ethical Analysis | 1 | 2014 | 53 | 0.490 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2013 | 128 | 0.480 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2023 | 7790 | 0.480 |
Why?
|
| Kidney | 6 | 2022 | 2265 | 0.470 |
Why?
|
| CHARGE Syndrome | 1 | 2014 | 9 | 0.470 |
Why?
|
| Prostatic Neoplasms | 10 | 2021 | 5996 | 0.460 |
Why?
|
| Supine Position | 3 | 2014 | 46 | 0.460 |
Why?
|
| Prospective Studies | 17 | 2024 | 13400 | 0.460 |
Why?
|
| Radiation Tolerance | 3 | 2018 | 636 | 0.460 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2015 | 141 | 0.460 |
Why?
|
| Nephrectomy | 9 | 2024 | 808 | 0.460 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 919 | 0.450 |
Why?
|
| Central Nervous System Neoplasms | 6 | 2024 | 550 | 0.450 |
Why?
|
| Abdominal Neoplasms | 4 | 2006 | 249 | 0.450 |
Why?
|
| Pinealoma | 2 | 2011 | 52 | 0.450 |
Why?
|
| Testicular Neoplasms | 2 | 2019 | 555 | 0.450 |
Why?
|
| Neck | 4 | 2009 | 386 | 0.430 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2021 | 2443 | 0.430 |
Why?
|
| Tomography, Emission-Computed | 3 | 2004 | 335 | 0.430 |
Why?
|
| Registries | 7 | 2024 | 2250 | 0.420 |
Why?
|
| Glioblastoma | 4 | 2023 | 1781 | 0.420 |
Why?
|
| Pediatrics | 3 | 2020 | 1184 | 0.410 |
Why?
|
| Fragile X Syndrome | 1 | 2013 | 154 | 0.400 |
Why?
|
| Incidence | 11 | 2021 | 5861 | 0.400 |
Why?
|
| Nose Neoplasms | 2 | 2012 | 236 | 0.390 |
Why?
|
| Cyclophosphamide | 8 | 2024 | 3231 | 0.390 |
Why?
|
| Dose-Response Relationship, Radiation | 10 | 2010 | 751 | 0.380 |
Why?
|
| Carcinosarcoma | 1 | 2012 | 149 | 0.380 |
Why?
|
| Clinical Decision-Making | 1 | 2014 | 534 | 0.380 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2016 | 1351 | 0.370 |
Why?
|
| Lung Neoplasms | 8 | 2018 | 12012 | 0.370 |
Why?
|
| Urogenital Neoplasms | 2 | 2010 | 115 | 0.360 |
Why?
|
| Infratentorial Neoplasms | 2 | 2001 | 48 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2017 | 3978 | 0.360 |
Why?
|
| Chemoradiotherapy | 4 | 2024 | 2029 | 0.360 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2023 | 159 | 0.350 |
Why?
|
| Clinical Competence | 2 | 2008 | 1327 | 0.350 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 1999 | 564 | 0.350 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2009 | 32 | 0.340 |
Why?
|
| Tumor Burden | 6 | 2021 | 2035 | 0.340 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2012 | 285 | 0.340 |
Why?
|
| Risk Factors | 16 | 2024 | 18045 | 0.340 |
Why?
|
| Survivors | 7 | 2022 | 1025 | 0.340 |
Why?
|
| Body Height | 1 | 2010 | 235 | 0.330 |
Why?
|
| Time Factors | 20 | 2024 | 13130 | 0.330 |
Why?
|
| Carcinoma | 4 | 2016 | 2623 | 0.330 |
Why?
|
| Intelligence | 3 | 2019 | 134 | 0.330 |
Why?
|
| Meningioma | 2 | 2009 | 307 | 0.330 |
Why?
|
| Fluorouracil | 3 | 2013 | 1988 | 0.330 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 5330 | 0.330 |
Why?
|
| Whole-Body Irradiation | 2 | 2010 | 324 | 0.320 |
Why?
|
| Dactinomycin | 6 | 2022 | 163 | 0.320 |
Why?
|
| Etoposide | 5 | 2024 | 905 | 0.320 |
Why?
|
| Doxorubicin | 9 | 2024 | 3131 | 0.320 |
Why?
|
| Educational Measurement | 2 | 2008 | 398 | 0.310 |
Why?
|
| Radiation Dosage | 8 | 2018 | 1043 | 0.310 |
Why?
|
| Brain | 8 | 2024 | 4252 | 0.310 |
Why?
|
| Middle Aged | 48 | 2024 | 90395 | 0.310 |
Why?
|
| Internship and Residency | 3 | 2024 | 1437 | 0.310 |
Why?
|
| Carotid Artery Diseases | 1 | 2009 | 177 | 0.300 |
Why?
|
| Infant, Newborn | 17 | 2021 | 8602 | 0.300 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 2054 | 0.300 |
Why?
|
| Disease Progression | 10 | 2022 | 6909 | 0.290 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2015 | 499 | 0.290 |
Why?
|
| Carcinoma, Papillary | 3 | 2018 | 580 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2018 | 5603 | 0.280 |
Why?
|
| Palliative Care | 4 | 2008 | 2159 | 0.280 |
Why?
|
| Maxillary Sinus Neoplasms | 2 | 1998 | 115 | 0.280 |
Why?
|
| Pain | 4 | 2012 | 1696 | 0.270 |
Why?
|
| Rhabdoid Tumor | 2 | 2023 | 111 | 0.270 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 809 | 0.270 |
Why?
|
| Sarcoma, Synovial | 2 | 2004 | 130 | 0.270 |
Why?
|
| Lymph Nodes | 4 | 2023 | 3080 | 0.260 |
Why?
|
| Proportional Hazards Models | 8 | 2023 | 5118 | 0.260 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 318 | 0.260 |
Why?
|
| Urethra | 2 | 2014 | 168 | 0.250 |
Why?
|
| Neurosurgical Procedures | 3 | 2023 | 634 | 0.250 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 787 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2021 | 609 | 0.240 |
Why?
|
| Sarcoma, Clear Cell | 2 | 2024 | 43 | 0.240 |
Why?
|
| Aged | 35 | 2024 | 73471 | 0.240 |
Why?
|
| Pineal Gland | 2 | 2007 | 49 | 0.240 |
Why?
|
| Homeostasis | 1 | 2010 | 959 | 0.240 |
Why?
|
| Pituitary Gland | 3 | 2018 | 157 | 0.240 |
Why?
|
| Prostatectomy | 4 | 2019 | 1006 | 0.230 |
Why?
|
| Spinal Neoplasms | 2 | 2021 | 666 | 0.230 |
Why?
|
| Intelligence Tests | 3 | 2022 | 89 | 0.230 |
Why?
|
| Carboplatin | 3 | 2024 | 879 | 0.220 |
Why?
|
| Age of Onset | 1 | 2006 | 852 | 0.220 |
Why?
|
| Supratentorial Neoplasms | 2 | 2004 | 79 | 0.220 |
Why?
|
| Radiotherapy, Computer-Assisted | 4 | 2009 | 127 | 0.220 |
Why?
|
| Subtraction Technique | 1 | 2003 | 143 | 0.210 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2004 | 199 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 1772 | 0.210 |
Why?
|
| Travel | 1 | 2024 | 200 | 0.210 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2022 | 20 | 0.210 |
Why?
|
| Societies, Medical | 1 | 2008 | 1349 | 0.200 |
Why?
|
| Necrosis | 1 | 2024 | 604 | 0.200 |
Why?
|
| Fibroma | 1 | 2022 | 86 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2010 | 2903 | 0.200 |
Why?
|
| Deafness | 1 | 2002 | 86 | 0.200 |
Why?
|
| Developing Countries | 1 | 2024 | 340 | 0.200 |
Why?
|
| Survivorship | 1 | 2022 | 117 | 0.200 |
Why?
|
| Insurance, Health | 2 | 2021 | 263 | 0.200 |
Why?
|
| Photosensitivity Disorders | 1 | 2001 | 22 | 0.200 |
Why?
|
| SEER Program | 6 | 2023 | 1047 | 0.200 |
Why?
|
| Aging | 1 | 2010 | 1578 | 0.190 |
Why?
|
| Dacarbazine | 3 | 2009 | 505 | 0.190 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2019 | 343 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2021 | 7929 | 0.190 |
Why?
|
| Leukemia | 2 | 2018 | 1721 | 0.190 |
Why?
|
| Amiodarone | 1 | 2001 | 51 | 0.190 |
Why?
|
| Radiography | 5 | 2015 | 1993 | 0.190 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 47 | 0.190 |
Why?
|
| Relative Biological Effectiveness | 2 | 2019 | 226 | 0.190 |
Why?
|
| Optic Nerve Glioma | 1 | 2021 | 28 | 0.190 |
Why?
|
| Paresis | 1 | 2021 | 54 | 0.190 |
Why?
|
| Hemiplegia | 1 | 2021 | 48 | 0.190 |
Why?
|
| Electrons | 1 | 2022 | 187 | 0.180 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 14653 | 0.180 |
Why?
|
| WAGR Syndrome | 1 | 2020 | 10 | 0.180 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 67 | 0.180 |
Why?
|
| Oligodendroglioma | 1 | 2021 | 106 | 0.180 |
Why?
|
| Aged, 80 and over | 17 | 2013 | 31042 | 0.180 |
Why?
|
| Gadolinium | 1 | 2021 | 172 | 0.180 |
Why?
|
| United States | 10 | 2024 | 16050 | 0.180 |
Why?
|
| Databases, Factual | 4 | 2020 | 2287 | 0.170 |
Why?
|
| Hypothalamus | 2 | 2018 | 276 | 0.170 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 77 | 0.170 |
Why?
|
| Proctitis | 1 | 2019 | 19 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2001 | 238 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2009 | 917 | 0.170 |
Why?
|
| Xerostomia | 1 | 2021 | 204 | 0.170 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 2359 | 0.170 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 77 | 0.160 |
Why?
|
| Deoxycytidine | 2 | 2016 | 1378 | 0.160 |
Why?
|
| Neoplasm Grading | 5 | 2019 | 1827 | 0.160 |
Why?
|
| Thyroid Gland | 4 | 2004 | 369 | 0.160 |
Why?
|
| Retinoblastoma | 2 | 2005 | 189 | 0.160 |
Why?
|
| Capecitabine | 2 | 2017 | 390 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 2 | 2011 | 427 | 0.160 |
Why?
|
| Orchiectomy | 1 | 2019 | 226 | 0.160 |
Why?
|
| Recurrence | 5 | 2023 | 4886 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2012 | 2417 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2021 | 272 | 0.160 |
Why?
|
| Urinary Incontinence | 1 | 2019 | 150 | 0.160 |
Why?
|
| Cognition Disorders | 3 | 2019 | 774 | 0.150 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2018 | 31 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 653 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 153 | 0.150 |
Why?
|
| Spine | 3 | 2007 | 311 | 0.150 |
Why?
|
| Ischium | 1 | 1997 | 11 | 0.150 |
Why?
|
| Ifosfamide | 2 | 2009 | 357 | 0.150 |
Why?
|
| Hearing | 1 | 2018 | 64 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 161 | 0.150 |
Why?
|
| Adenocarcinoma | 5 | 2009 | 7975 | 0.150 |
Why?
|
| Salvage Therapy | 5 | 2021 | 2119 | 0.150 |
Why?
|
| Tablets | 2 | 2017 | 56 | 0.150 |
Why?
|
| Cranial Fossa, Posterior | 3 | 2003 | 50 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 322 | 0.150 |
Why?
|
| Cystectomy | 2 | 2019 | 632 | 0.140 |
Why?
|
| Risk | 2 | 2019 | 1950 | 0.140 |
Why?
|
| Analysis of Variance | 4 | 2015 | 2337 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2014 | 4352 | 0.140 |
Why?
|
| Data Collection | 1 | 2019 | 624 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2010 | 7300 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2014 | 1237 | 0.140 |
Why?
|
| Bleomycin | 1 | 2018 | 482 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 559 | 0.140 |
Why?
|
| Executive Function | 1 | 2017 | 149 | 0.130 |
Why?
|
| Splenomegaly | 1 | 1996 | 173 | 0.130 |
Why?
|
| Prone Position | 2 | 2014 | 60 | 0.130 |
Why?
|
| Parotid Gland | 3 | 2021 | 116 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 908 | 0.130 |
Why?
|
| Attention | 1 | 2017 | 286 | 0.130 |
Why?
|
| Myositis | 1 | 2016 | 88 | 0.130 |
Why?
|
| Spinal Cord | 1 | 1999 | 724 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 1065 | 0.120 |
Why?
|
| Carmustine | 1 | 2005 | 224 | 0.120 |
Why?
|
| Retreatment | 3 | 2021 | 447 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 562 | 0.120 |
Why?
|
| Liver Neoplasms | 4 | 2010 | 4809 | 0.120 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2014 | 34 | 0.120 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2014 | 10 | 0.120 |
Why?
|
| Thoracic Neoplasms | 2 | 2012 | 349 | 0.120 |
Why?
|
| Biomarkers, Tumor | 6 | 2022 | 10750 | 0.120 |
Why?
|
| Urination Disorders | 1 | 2014 | 63 | 0.120 |
Why?
|
| Postoperative Care | 2 | 2016 | 731 | 0.120 |
Why?
|
| North America | 1 | 2014 | 341 | 0.110 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 154 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1996 | 382 | 0.110 |
Why?
|
| Histones | 1 | 2021 | 1514 | 0.110 |
Why?
|
| Anaplasia | 2 | 2024 | 18 | 0.110 |
Why?
|
| Radiometry | 4 | 2022 | 1017 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 656 | 0.110 |
Why?
|
| Retroperitoneal Space | 1 | 2013 | 156 | 0.110 |
Why?
|
| Brachytherapy | 4 | 2014 | 1005 | 0.110 |
Why?
|
| Vision Disorders | 3 | 2021 | 241 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2021 | 1544 | 0.100 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 1047 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2006 | 1913 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 4507 | 0.100 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2012 | 39 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 2 | 2000 | 5248 | 0.100 |
Why?
|
| Tomography, Spiral Computed | 2 | 2009 | 128 | 0.100 |
Why?
|
| Prostate | 1 | 1997 | 1138 | 0.100 |
Why?
|
| Mastectomy | 1 | 2018 | 1557 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2015 | 802 | 0.100 |
Why?
|
| Muscles | 2 | 2004 | 461 | 0.090 |
Why?
|
| Intestine, Small | 3 | 2009 | 527 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 5928 | 0.090 |
Why?
|
| Social Adjustment | 2 | 2022 | 115 | 0.090 |
Why?
|
| Growth Hormone | 2 | 2021 | 227 | 0.090 |
Why?
|
| Central Nervous System | 1 | 2013 | 457 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2021 | 2761 | 0.090 |
Why?
|
| Tunica Media | 1 | 2009 | 20 | 0.090 |
Why?
|
| Lymphatic System | 1 | 2009 | 56 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4399 | 0.090 |
Why?
|
| Amifostine | 1 | 2010 | 99 | 0.090 |
Why?
|
| Groin | 1 | 2009 | 78 | 0.090 |
Why?
|
| Patient Care Planning | 2 | 2005 | 306 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2004 | 5566 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 5195 | 0.080 |
Why?
|
| Tinea Capitis | 1 | 2009 | 6 | 0.080 |
Why?
|
| Trigeminal Neuralgia | 1 | 2009 | 42 | 0.080 |
Why?
|
| Tunica Intima | 1 | 2009 | 100 | 0.080 |
Why?
|
| Foot | 1 | 2009 | 108 | 0.080 |
Why?
|
| Loss of Heterozygosity | 2 | 2023 | 626 | 0.080 |
Why?
|
| Pharynx | 2 | 2000 | 150 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 1996 | 881 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 196 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2021 | 3664 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2010 | 1039 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 4071 | 0.080 |
Why?
|
| Ureteral Obstruction | 1 | 2010 | 162 | 0.080 |
Why?
|
| Thigh | 1 | 2009 | 164 | 0.080 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2008 | 32 | 0.080 |
Why?
|
| Mechanics | 1 | 2007 | 3 | 0.080 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2007 | 9 | 0.080 |
Why?
|
| Age Distribution | 1 | 2010 | 730 | 0.080 |
Why?
|
| Niacinamide | 1 | 2009 | 427 | 0.080 |
Why?
|
| Mandible | 2 | 2000 | 191 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 835 | 0.070 |
Why?
|
| Cellular Senescence | 1 | 2010 | 390 | 0.070 |
Why?
|
| Lymphatic Irradiation | 2 | 2018 | 139 | 0.070 |
Why?
|
| International Cooperation | 2 | 2019 | 326 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2014 | 6883 | 0.070 |
Why?
|
| Particle Accelerators | 2 | 2007 | 362 | 0.070 |
Why?
|
| Rectum | 3 | 2013 | 479 | 0.070 |
Why?
|
| Camptothecin | 1 | 2009 | 538 | 0.070 |
Why?
|
| Head | 1 | 2008 | 249 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 1707 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3704 | 0.070 |
Why?
|
| Organs at Risk | 1 | 2010 | 560 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 16241 | 0.070 |
Why?
|
| Lung | 1 | 2018 | 3294 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 546 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 600 | 0.070 |
Why?
|
| Quality of Life | 4 | 2023 | 4749 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2006 | 42 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 1175 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 371 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2006 | 97 | 0.060 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 379 | 0.060 |
Why?
|
| Endocrine System Diseases | 2 | 2018 | 91 | 0.060 |
Why?
|
| Unnecessary Procedures | 1 | 2006 | 102 | 0.060 |
Why?
|
| Phantoms, Imaging | 2 | 2022 | 1330 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 4891 | 0.060 |
Why?
|
| Placebos | 1 | 2006 | 446 | 0.060 |
Why?
|
| Remission Induction | 3 | 2012 | 3645 | 0.060 |
Why?
|
| Laminectomy | 1 | 2005 | 52 | 0.060 |
Why?
|
| Urography | 2 | 2010 | 58 | 0.060 |
Why?
|
| Philippines | 1 | 2024 | 42 | 0.060 |
Why?
|
| Peripheral Nervous System | 1 | 2004 | 51 | 0.060 |
Why?
|
| Biopsy | 3 | 2021 | 3544 | 0.060 |
Why?
|
| Fibrosarcoma | 1 | 2004 | 142 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 1177 | 0.060 |
Why?
|
| Adenoma | 1 | 2009 | 745 | 0.060 |
Why?
|
| Pelvic Neoplasms | 2 | 2004 | 203 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 2053 | 0.060 |
Why?
|
| Arm | 1 | 2004 | 138 | 0.060 |
Why?
|
| Atrophy | 1 | 2004 | 279 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2009 | 1572 | 0.060 |
Why?
|
| Sex Factors | 1 | 2009 | 2206 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2018 | 1588 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 3853 | 0.060 |
Why?
|
| Radioisotope Teletherapy | 1 | 2003 | 11 | 0.060 |
Why?
|
| Leg | 1 | 2004 | 216 | 0.050 |
Why?
|
| Immobilization | 1 | 2003 | 91 | 0.050 |
Why?
|
| Survival | 1 | 2003 | 184 | 0.050 |
Why?
|
| Fees, Medical | 1 | 2002 | 12 | 0.050 |
Why?
|
| Contrast Media | 2 | 2021 | 1510 | 0.050 |
Why?
|
| Posture | 1 | 2003 | 204 | 0.050 |
Why?
|
| Pyridines | 1 | 2009 | 1312 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2022 | 87 | 0.050 |
Why?
|
| Gonads | 1 | 2002 | 52 | 0.050 |
Why?
|
| Hospital Charges | 1 | 2002 | 89 | 0.050 |
Why?
|
| Radiation Protection | 1 | 2003 | 204 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 3539 | 0.050 |
Why?
|
| Transplants | 1 | 2002 | 51 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 338 | 0.050 |
Why?
|
| Cause of Death | 1 | 2005 | 787 | 0.050 |
Why?
|
| Sternum | 1 | 2002 | 96 | 0.050 |
Why?
|
| Curriculum | 1 | 2007 | 910 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 686 | 0.050 |
Why?
|
| Tooth Abnormalities | 1 | 2021 | 14 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 53 | 0.050 |
Why?
|
| Fourth Ventricle | 1 | 2021 | 50 | 0.050 |
Why?
|
| Insurance Carriers | 1 | 2021 | 12 | 0.050 |
Why?
|
| Dentition | 1 | 2000 | 7 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 1240 | 0.050 |
Why?
|
| Facial Asymmetry | 1 | 2000 | 21 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2004 | 612 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2002 | 96 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2021 | 140 | 0.050 |
Why?
|
| Morbidity | 1 | 2002 | 405 | 0.050 |
Why?
|
| Puberty, Delayed | 1 | 2000 | 7 | 0.050 |
Why?
|
| Thalamus | 1 | 2021 | 123 | 0.040 |
Why?
|
| Growth | 1 | 2000 | 125 | 0.040 |
Why?
|
| Kyphosis | 1 | 2000 | 45 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2019 | 9491 | 0.040 |
Why?
|
| Cloud Computing | 1 | 2019 | 15 | 0.040 |
Why?
|
| Testis | 1 | 2004 | 753 | 0.040 |
Why?
|
| Illinois | 1 | 1999 | 27 | 0.040 |
Why?
|
| MEDLINE | 1 | 1999 | 35 | 0.040 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2001 | 115 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 268 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2020 | 206 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2003 | 592 | 0.040 |
Why?
|
| Educational Status | 1 | 2000 | 393 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2020 | 276 | 0.040 |
Why?
|
| Child Development | 1 | 2020 | 267 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2005 | 948 | 0.040 |
Why?
|
| Diatrizoate | 1 | 1997 | 12 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 6515 | 0.040 |
Why?
|
| Barium Sulfate | 1 | 1997 | 41 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1116 | 0.040 |
Why?
|
| Diatrizoate Meglumine | 1 | 1997 | 22 | 0.040 |
Why?
|
| Income | 1 | 2018 | 232 | 0.040 |
Why?
|
| Larynx | 1 | 1999 | 144 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 5750 | 0.040 |
Why?
|
| Breast | 1 | 2004 | 1380 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 2000 | 224 | 0.040 |
Why?
|
| Fertility | 1 | 2000 | 347 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2002 | 699 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2020 | 442 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 314 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 1104 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2017 | 257 | 0.030 |
Why?
|
| Demography | 1 | 2018 | 435 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2021 | 861 | 0.030 |
Why?
|
| Intersectoral Collaboration | 1 | 2016 | 42 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 355 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1068 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2002 | 882 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 312 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2020 | 957 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 6986 | 0.030 |
Why?
|
| Skull Neoplasms | 1 | 1996 | 68 | 0.030 |
Why?
|
| Abdomen | 1 | 1998 | 348 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1997 | 636 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 358 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 796 | 0.030 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 72 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 215 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 360 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2023 | 1463 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 1730 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2000 | 732 | 0.030 |
Why?
|
| Heart | 1 | 2020 | 1214 | 0.030 |
Why?
|
| Urogenital System | 1 | 2014 | 62 | 0.030 |
Why?
|
| Urinary Bladder | 2 | 2009 | 601 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 864 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 1620 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2014 | 222 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 2624 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 323 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 1100 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 89 | 0.030 |
Why?
|
| Texas | 2 | 2013 | 6435 | 0.020 |
Why?
|
| Algorithms | 1 | 2023 | 3923 | 0.020 |
Why?
|
| Medical Records | 1 | 2013 | 447 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1262 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2352 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1212 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 4889 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2013 | 946 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1998 | 1943 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1209 | 0.020 |
Why?
|
| Logistic Models | 1 | 2018 | 3469 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2012 | 250 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2335 | 0.020 |
Why?
|
| Femur Head | 1 | 2009 | 42 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1323 | 0.020 |
Why?
|
| Laser Therapy | 1 | 2014 | 465 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5186 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 522 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 1999 | 2429 | 0.020 |
Why?
|
| Radiobiology | 1 | 2008 | 56 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 2317 | 0.020 |
Why?
|
| Pelvis | 1 | 2009 | 384 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 675 | 0.020 |
Why?
|
| Forecasting | 1 | 2010 | 706 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 1155 | 0.020 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2006 | 15 | 0.020 |
Why?
|
| Metalloporphyrins | 1 | 2006 | 31 | 0.020 |
Why?
|
| Medicare | 1 | 2011 | 934 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 1016 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2006 | 102 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2267 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2006 | 221 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 566 | 0.010 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 2004 | 74 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 366 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 5211 | 0.010 |
Why?
|
| Film Dosimetry | 1 | 2004 | 62 | 0.010 |
Why?
|
| Intestine, Large | 1 | 2003 | 32 | 0.010 |
Why?
|
| Stents | 1 | 2010 | 1015 | 0.010 |
Why?
|
| Iowa | 1 | 2002 | 17 | 0.010 |
Why?
|
| Episode of Care | 1 | 2002 | 9 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 754 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15924 | 0.010 |
Why?
|
| Microcirculation | 1 | 2000 | 195 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 330 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 423 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2000 | 252 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 967 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 2679 | 0.010 |
Why?
|
| Sacrum | 1 | 1998 | 139 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2003 | 1552 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 2003 | 791 | 0.010 |
Why?
|
| Comorbidity | 1 | 2002 | 2439 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 62807 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2003 | 1389 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 4998 | 0.010 |
Why?
|
| Smoking | 1 | 2002 | 2538 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 6236 | 0.010 |
Why?
|